Karim and I Both Agree: Accumulate This Stock on Dips
If you recall…
As soon as the coronavirus news was getting started in late February, my very first reaction was to buy Clorox (NYSE: CLX).
I’ve been pretty outspoken about this Clorox play, so I’m sure you’ve heard me beat this drum before.
However, here’s what you may not have realized…
After Clorox, my second reaction was to move into Pfizer (NYSE: PFE).
In fact, Karim agreed with me, which is why Pfizer was part of Karim’s wish list of names to buy on the dip.
And right now, I’m here to tell you that Pfizer remains a top play to continue accumulating. Why?
Let me detail it for you. But I must warn you: The statistics that I’m about to share are depressing.
In all honesty, the sad truth is that America could be on the verge of a mental health crisis – as loneliness from social distancing takes a toll on the public’s psychological health.
Right now, 4 in 10 Americans are feeling lonelier than ever before (according to a survey of 1,055 people commissioned by the University of Phoenix).
Twenty-two percent of Americans said that their sleep quality has suffered since the coronavirus spread.
And 35% of Americans said that their mental health has worsened during the pandemic, while 43% said their emotional well-being has also gotten worse.
As sad as these statistics are, every one of them makes a strong case for owning Pfizer.
And no wonder…
You see, based on these results, it’s clear that Americans are now filling more prescriptions for antidepressants and anti-insomnia drugs.
Specifically, antianxiety drugs saw the biggest spike, jumping 34.1%, which was more than double the number of insomnia aids (14.8%) and almost twice as high as antidepressants (18.6%).
As you may have guessed, one of the bestselling antianxiety meds on the market right now is Pfizer’s Xanax.
Action Plan: Mental health is a real thing. It costs the healthcare system more than $200 billion a year, making it one of the country’s most expensive health conditions. And now, with the stay-at-home orders, matters are even worse. This is why a play like Pfizer represents a safe haven in today’s new pandemic-driven world.
P.S. Did you hit a huge overnight winner on Snap today?
These War Room members did. Isn’t it time you joined them in The War Room?
“I only took the call on Snap, got in at $1.11 and got out at $2.74. Got lucky for a change.” – Ancil
“I’m not a rocket surgeon, but that looks like my best trade so far… 156% Thanks BB.” – Michael K.
“108% gain on SNAP. Biggest gain for me thus far! Thank you Bryan!!” – Paula T.
“First play in The War Room. SNAP May $13 call… in @ $1.12 out at $2.67, 138% gain. Thank you for the education.” – Bernie C.
“Nice call again Bryan! 116% gain Up $116 on each contract, lovely way to start the day!” – Rick R.
“Calls: in @ $1.08, out @ $2.77.” – Michael K.
“Only bought the calls. In @ $1.08 out @ $2.42. Great start to the day. Thanks Bryan.” – Wade K.
About Bryan Bottarelli
Bryan graduated with a business degree from the highly rated Indiana University Kelley School of Business, and his first job out of college was trading stock options on the floor of the Chicago Board Options Exchange. He was mentored by some of the country’s top floor traders in the heart of the technology boom from 1999 to 2000, where he learned to identify and implement some of his most powerful trading secrets. Now he shares his secrets with a group of elite traders. We will be republishing some of his highly sought after content from his free e-letter, Trade of the Day.